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Background: Although it was initially assumed that erythropoietin (EPO) was a hormone that only affected
erythropoiesis, it has now been proposed that EPO plays an additional key role in the regulation of acute and
chronic tissue damage.
Via the inhibition of inflammatory reactions and of apoptosis, stem cell recruitment, advancement of angiogenesis
and growth factor release, EPO enhances healing and thus restitutio ad integrum after trauma. Human skin contains
EPO receptors and is able to synthesize EPO. We therefore hypothesize that EPO is able to optimize wound healing
in thermally injured patients.
Methods/Design: This is a large, prospective, randomized, double-blind, multi-center study, funded by the German
Federal Ministry of Education and Research, and fully approved by the designated ethics committee. The trial,
which is to investigate the effects of EPO in severely burned patients, is in its recruitment phase and is being
carried out in 13 German burn care centers. A total of 150 patients are to be enrolled to receive study medication
every other day for 21 days (EPO 150 IU/kg body weight or placebo). A follow-up of one year is planned. The
primary endpoint of this study is the time until complete re-epithelialization of a defined skin graft donor site is
reached. Furthermore, clinical parameters such as wound healing, scar formation (using the Vancouver scar scale),
laboratory values, quality of life (SF-36), angiogenic effects, and gene- and protein-expression patterns are to be
determined. The results will be carefully evaluated for gender differences.
Discussion: We are seeking new insights into the mechanisms of wound healing in thermally injured patients and
more detailed information about the role EPO plays, specifically in these complex interactions. We additionally
expect that the biomimetic effects of EPO will be useful in the treatment of acute thermal dermal injuries.
Trial registration: EudraCT Number: 2006-002886-38, Protocol Number: 0506, ISRCT Number: http://controlled-trials.
com/ISRCTN95777824/ISRCTN95777824.
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Over the past few years, our understanding of erythro-
poietin (EPO) has changed significantly. Although it was
initially assumed that EPO was a hormone affecting
erythropoiesis only [1], it has now been discussed that
EPO plays a key role in the repair of acute and chronic
tissue damage. It has also been proposed that EPO has a
significant anti-inflammatory effect, whereby the inflam-
matory response is part of the normal reaction of any or-
ganism to injury. Via the inhibition of inflammatory
reactions, EPO influences healing and thus promotes
restitutio ad integrum after trauma [2].
In addition, EPO seems to be involved in ensuring that
stem cells are recruited to the required location. The
best-known effect is the endothelial nitric oxide synthase
(eNOS) mediated response and the recruitment of endo-
thelial progenitor cells (EPCs) [3]. In vitro data show
enhancement of stem cell proliferation and stem cell
phenotype-conservation caused by EPO in human
mesenchymal dermal stem cells grown under hypoxic
conditions and in IL-6 enriched media [4].
Additionally, there are numerous publications reporting
EPO’s function as a protective molecule of capillary endo-
thelial cells, which under hypoxic stress would normally
become apoptotic, thus improving the blood supply in the
surrounding tissues [5]. In many tissues, inhibition of
apoptosis is induced directly via a phosphorylation cascade
initiated by the EPO receptor. Numerous pathways can be
attributed to phosphorylation of janus kinase 2 (JAK-2)
and subsequent phosphorylation of signal transducers
and activators of transcription (STATs) and B-cell
lymphoma extra-large (BCL-XL) or are mediated via
phosphatidylinositol-3 kinase (protein kinase A) (PI3K-Akt)
and mitogen-activated protein kinase (MAPK) pathways
[6,7]. STAT then evokes apoptotic inhibition in the nucleus.
Furthermore, Akt (protein kinase B) is activated, which
plays a central role in cell survival [8].
Several authors report that EPO also triggers a variety of
growth factors (see Table 1). Since we are focusing our
discussion onto factors which are known to be involved in
wound healing, the present work describes a selected
number of growth factors and their effects.
Several publications indicate that the actions of spe-
cialized proinflammatory cells, such as leukocytes and
macrophages, are down-regulated by EPO: the pro-
duction of IL-2, IL-6, IL-8, γ-interferon and tumor
necrosis factor α (TNF-α) is antagonized [10,14,25].
Normal human skin contains EPO receptors and is able
to synthesize EPO. In culture, under hypoxic conditions,
EPO synthesis increases [26].
In a mouse model the combined presence of EPO re-
ceptor (EPOR) and the EPO-hetero-receptor could be
demonstrated in healthy and scalded skin. Additionally,
after systemic EPO application the EPOR was significantlydown-regulated in the healthy skin; by contrast, in the
scalded skin, the expression rate stayed unchanged [27].
Several investigations on the effects of EPO on wound
healing have shown predominantly elevated vascular
endothelial growth factor (VEGF) and endothelial
growth factor levels (and resulting elevated capillary
density) in treatment groups compared to controls. This
was emphasized by increased cluster of differentiation
31 (CD31) gene expression. Higher protein and collagen
densities, as well as the greater mechanical stability of
fresh cicatrices, were found in treatment groups as
well [28].
One of the first research projects to examine the effects
of EPO on wound healing, used fibrin-filled subcutaneously
implanted chambers. These chambers were then injected
with an EPO/fibrin mixture with different concentrations
of EPO. The formation of granulation tissue was stimulated
by the administration of EPO. When an anti-EPO or
anti-EPO receptor antibody was added, the formation
of granulation tissue deteriorated [29].
An in vitro study examined the effects of EPO and
EPO receptors in human hair follicles. It was shown that
hair follicle cells produce EPO and EPO receptors and
that EPO shows its typical tissue-protective effects.
Protective effects against chemotherapy-induced apoptosis
of hair follicle cells was demonstrated [26]. Skin-derived
EPO appears to act locally, while it is less important for
the systemic EPO response to acute hypoxia in healthy
humans [30].
The effects of subcutaneous EPO on dermal regener-
ation were also investigated using nude mice. In this
model, the healing of a full thickness defect was traced
directly into the skin-fold chamber in nude mice. It
was shown that with EPO the healing process not
only improved but was also accelerated depending on
the dosage [31].
In another mouse model, after thermal trauma and
subsequent EPO treatment, improved and accelerated
wound healing was observed compared to the control
group [32]. This was marked by increased epithelial
proliferation, maturation of the extra-cellular matrix,
increased angiogenesis and increased capillary dens-
ity, identified by high CD31, VEGF values and eNOS
activity. When mice were administered anti-EPO
antibodies, wound healing deteriorated below that of
the control group. After thermal trauma in mice and
subsequent EPO treatment, mice exhibited improved
and accelerated re-epithelialization as well as faster
wound healing compared to control groups. This was
characterized by increased epithelial proliferation,
and maturation of extra-cellular matrices, as well as
increased angiogenesis and capillary density detect-
able via high CD31 and VEGF values and eNOS
activity [32].
Table 1 Most important effects of EPO on different growth factors in wound healing
Factor Action EPO action Tissue, organ, species Reference
TNF-α Primary-injury response Antagonist Neuronal tissue, brain, mice [9]
IL-2, -6, -8 Proinflammatory cytokines Inhibition Human histiocytic lymphoma cells [10]
[11]
γ-interferon Proinflammatory cytokine Inhibition Human histiocytic lymphoma cells [10]
MIP 1 u. 2 Proinflammatory protein Inhibition Cartilage, mice (arthritis model) [12]
Myeloperoxidase Invasion-marker for macrophages Inhibition Neuronal tissue, brain, mice [13]
IL-1β Proinflammatory cytokine Inhibition Human histiocytic lymphoma cells [10]
γ-interferon Proinflammatory cytokine Inhibition Human leucocytes [14]
VEGF Angiogenesis Stimulation Skin, microvessels, mice [15]
eNOS Recruitment of EPCs Stimulation Skin, microvessels, mice [16]
EGF Angiogenesis Stimulation Heart, microvessels, neovasculature, rat [17]
HIF-1α / HIF-2α Adaption to hypoxia, stimulation of EPO and VEGF Stimulation Human hepatoma cell lines [18]
EPAS 1 Adaption to hypoxia Stimulation Cortical astrocytes [19]
Cortical astrocytes [19]
iNOS Relaxation of smooth muscle cells Stimulation Skin, microvessels, mice [15]
BCL-Xl Anti-apoptotic Stimulation Erythroid progenitor cell line, mice [20]
IGF-I Anti-apoptotic Stimulation Astrocytoma cell line [21]
cell proliferation
Caspase-3 Apoptosis Inhibition Kidney, rat [22]
BCL-2 Anti-apoptotic Stimulation Erythroid progenitor cell line, mice [23]
proliferation
hsp 70 Intracellular protective processes Stimulation Human TF-1 cell line [24]
BCL: B-cell lymphoma; EGF: endothelial growth factor; eNOS: endothelial nitric oxide synthase; EPAS: endothelial PAS domain-containing protein; EPC: endothelial
progenitor cell; hsp: heat shock protein; IGF: insulin-like growth factor; iNOS: inducible nitric oxide synthase; MIP: macrophage inflammatory protein; TNF: tumor
necrosis factor; VEGF: vascular endothelial growth factor.
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represents a new, effective therapeutic opportunity for
the treatment of acute dermal thermal injuries.Methods/Design
This study is conducted according to globally accepted
standards of good clinical practice (as defined in the
ICH E6 Guideline for Good Clinical Practice, 1 May
1996), in agreement with the Declaration of Helsinki
and in keeping with local regulations. It has full
approval of the designated ethic committee (at the
University of Lübeck, Ratzeburger Allee 160, Building
21, 23562 Lübeck, Germany) and is funded by the
German Federal Ministry of Education and Research.
Additionally, the study received support for medication
costs from Heraeus Holding GmbH.Objectives
The study objectives are to demonstrate a cytoprotective
and regenerative effect of erythropoietin in thermally
injured patients in terms of reduced morbidity andmortality and to better understand the cellular mechanisms
of erythropoietin in skin graft donor sites (SGDSs) and
second-degree wounds (SDWs).Study design
This is a prospective, randomized, double-blind, multi-
center clinical trial, conducted in 13 burn care centers in
Germany. In total, 150 adult patients with burn and scald
injuries will be included.
Via a centralized randomization list, patients are ran-
domly allocated to the drug- or the placebo-treated
group. Patients receive normal state-of-the-art burn care
treatment plus study medication every other day. Study
wound sites (SGDCs and SDWs) are treated with stand-
ard wound dressings. Dressing changes, wound docu-
mentation, photo documentation, biopsies, control of
safety parameters, study medication and other relevant
actions are strictly regulated in the study protocol. The
acute treatment and observational phase is 28 days, with
follow-up controls at Day 42, after 6 months and 12
months after inclusion.
Table 2 Composition of placebo solution
Substance Amount
NaCl 8.24 g
Benzyl alcohol 3.67 g
Benzalkonium chloride 0.58 g
H2O ad injectionem Ad 1,000 ml
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Adult patients between 18 and 75 years of age with deep
burns (deep second (2b) or third degree) or scalding
injuries between 5% and 60% of total body surface (TBS)
(patients under 40 can have more than a 60% TBS
injury), and where a necrectomy and consecutive split skin
graft transplantation is indicated, are to be included in the
trial. Patients who are either pregnant or breastfeeding are
to be excluded. Informed consent in written form must be
given before the first study-specific action, by the patient,
the patient’s legal representative or via the Heidelberger
Verfahren. The Heidelberger Verfahren, first described by
Brückner et al. [33], allows recruitment of patients who are
unable to give informed consent themselves and where
there is insufficient time to appoint a legal representative.
In such cases, a judge, in consensus with the ethics com-
mittee and the judicial court, decides whether a patient can
take part in the trial and gives the patient’s next-of-kin the
authority to give informed consent on behalf of the patient.
However, in cases where a next-of-kin is not available or
unknown, the judge has the legal authority to give informed
consent in advance and simultaneously a legal representa-
tive will be designated, who will subsequently give informed
consent. Additionally as soon as the patient is able to give
informed consent, he or she will be asked to do so.
Inclusion criteria
3° burn and scalding thermal injuries obligate, 2° burn
and scalding thermal injuries optional, which require
operations including split skin harvesting and grafting
Men and women, age ≥ 18 and ≤ 75 years
Secure contraception.
Exclusion criteria
Admission later than 24 hours after injury.
Hematological disorders (anemia, lymphoma, leukemia,
inborn coagulation diseases).
Pregnancy or breast-feeding.
Estimated survival shorter than one week (abbreviated
burn severity index (ABSI) > 12) in patients older than
40 years of age.
Body weight < 50 kg or > 110 kgTotal burn surface
area involved less than 60% in patients older than 40
years of age.
In patients below 40 years of age no limitation of
maximum burned body surface and no limitation of
ABSI score will be considered.
Upper lateral thighs of both legs thermally injured.
Subject is the investigator or any sub-investigator,
research assistant, pharmacist, study coordinator, other
staff or relative thereof directly involved in the conduct
of the protocol.Subject is unlikely to comply with protocol, e.g.,
uncooperative attitude, inability to return for follow-up
visits, and unlikelihood of completing the study.
Treatment with any investigational product in the last
12 months before study entry.
Treatment with any immunosuppressive therapy,
cancer-related chemotherapy or radiation therapy in
the past 12 months.
History of hypersensitivity to the investigational
products.
Likelihood of requiring treatment during the study
period with drugs not permitted by the clinical study
protocol.
Clinically relevant cardiovascular (s.p. cardiac
infarction, coronary heart disease (CHD),
treatmenresistant hypertension, thromboembolic
disease, thromboembolic events shortly before
admission), hepatic (Child B or C liver disease),







Randomized patients receive state-of-the-art burn care
treatment including (depending on the clinical situation
of the individual patient) analgosedation, respiration,
escharectomy and split skin grafting or, if necessary, tem-
porary wound closure. General wound care and wound
dressings can be used, as they are standard practice in the
study centers. The only exceptions are the studied split
SGDS, the studied second-degree wound and the studied
third-degree wound, which have to be treated as described
in detail in the study protocol.
The study medication is either 150 IU recombinant
human EPO (rhEPO) (NeoRecormon Multidose 50,000
IU, Roche, Grenzach-Wylen, Germany) per kilogram of
body weight or a matched placebo (see Table 2), which
is administered every other day subcutaneously for 21
days. The split SGDS is to be generated on Day 2 of
study treatment and special wound dressings with a
polyurethane foil have to be applied according to the
trial protocol. Dressing changes and wound controls are
Günter et al. Trials 2013, 14:124 Page 5 of 8
http://www.trialsjournal.com/content/14/1/124made at specified time points. Patients receive a standard-
ized anticoagulant therapy with body weight-adjusted
intravenous heparin.
Measurements
Race, gender, age, height, weight, TBS burned percentage,
severity of burn (grades 1, 2a, 2b or 3), ABSI and concomi-
tant illnesses or injuries will be documented upon admis-
sion. Woman of reproductive age will undergo a pregnancy
test to check for an unknown pregnancy.
Daily controls of the organ failure parameters, using
the sequential organ failure assessment (SOFA), and safety
relevant parameters will be performed. The wound will be
clinically assessed and photographs taken according to the
protocol. Special EPO-related blood samples will be taken
once a week for four consecutive weeks. Punch biopsies
will be performed from the SGDS and the SDW four
times and once from healthy skin as a control.
Primary endpoint
The primary endpoint is the time until complete re-
epithelialization of the SGDS at a specified location on
the lateral upper thigh.
Secondary endpoints
Time until complete wound healing of type 2a SDW
– Time until complete wound healing of skin graft.
– Cellular and molecular regenerative effects in SGDS
and type 2a SDW, Endothelial.
Progenitor Cell (EPC) recruitment, EPO receptor
up-or down-regulation, protein-, RNA- and microRNA-
expression patterns
– Quality of scar formation in conservatively and
operatively treated wound locations.
– Number of packed red cells units, which are
transfused during the treatment interval- Organ
dysfunction parameters- Quality of life 12 months
after trauma (SF-36)- Mortality (within 21 days,
during the hospital stay and 1 year on).
– Adverse events (AEs), Serious Adverse Events
(SAEs), Suspected Unexpected Serious.
Adverse Reactions (SUSARs)
– Gender differences in monitored data.
Safety data
The safety endpoints include AEs, SAEs, SUSARs, labora-
tory test results and vital signs. The data safety monitoring
board (DSMB) will supervise the occurrence of AEs, SAEs,
SUSARs and overall safety parameters.A group of independent experts will form the Safety
Monitoring Board. The DSMB will independently review
the safety data for the duration of the study. In addition,
the coordinating investigator will inform the DSMB of
any SUSARs with a written report.
The DSMB will give advice when specific actions are
necessary. The study sites will be immediately informed
of the procedures. The DSMB will discontinue the study
if a quantitative accumulation of SAEs is observed. In
addition, if there is an unexpected accumulation of SAEs
other than mentioned above during the study, the
DSMB will discontinue the study. Additionally, annual
safety and progress reports have to be prepared for the
authorities and the independent ethics committees.
Statistical considerations
Sample size justification
Under conventional treatment, complete re-epithelialization
of split skin graft donor sites occurs after a mean of 10 to
15 days with a standard deviation (SD) of about 6 days,
depending on the donor site and the patient’s general condi-
tion. We expect that EPO treatment can reduce the total
healing time by at least 4 days. Sample size calculation with
alpha = 0.05 and beta = 0.10 thus indicates that 48 evaluable
patients per group are necessary. In order to have 96
patients with valid data for the intention-to-treat analysis of
the primary outcome, we aim to include 150 patients. This
allows for 54 dropouts (34%).
Statistical analysis
Analyses will include all randomized patients with at
least one exposure to the study drug. In addition to the
intention-to-treat population, an exploratory analysis of all
patients completing the study as planned (per protocol
analysis) will be carried out. Standard statistical testing
will be used to examine the superiority of one treatment
arm. Testing will be adjusted for two stratification factors:
ABSI group and hospital. The primary endpoint for the
time taken for re-epithelialization of the skin graft donor
site will be analyzed as a continuous variable with normal
distribution. A safety analysis will be carried out for all
adverse events (regardless of severity). According to
current standards, the safety analysis will exclude those
patients who failed to receive any study drug dose. A list
of all adverse events will be provided and periodically
distributed to the DSMB. The two-sided significance level
for the final analysis is 0.05.
Discussion
The primary aim of this study is to evaluate the effect of
repetitive low dose rhEPO administered within 21 days
in severely thermally injured patients. There are several
reasons to believe that repetitive low dose rhEPO will
improve wound healing in this patient population
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tions. rhEPO is a well-known drug and has been used
for nearly 30 years in daily clinical practice to treat
anemia [34]. Thus the risk/benefit ratio for patients is
relatively concrete to estimate, and will be discussed
later. In addition the erythropoietic response to EPO is
markedly decreased in thermally injured patients [35,36].
During the last two decades of the 20th century, scien-
tific interest has turned towards treating burned patients
with EPO, especially those patients who refuse blood
transfusions and blood products due to religious reasons
[35,36]. Several single-case reports have been published
and two trials have been performed on thermally injured
patients in intensive burn care units in an attempt to
improve erythropoiesis. Both trials failed to show that doses
between 300 and 500 IU rhEPO per kilogram of body
weight daily for 7 days could significantly reduce the
amount of required red blood cell transfusions. No statisti-
cally significant differences in hemoglobin, hematocrit,
reticulocyte count, ferritin, serum iron, total iron binding
capacity or transfusion requirements were found in either
study. The effects on wound healing were not within the
scope of the studies and therefore not monitored. In
patients with burns involving 25% to 35% of total body sur-
face, the reticulocyte counts were statistically significantly
higher. In one trial it became evident that iron supplemen-
tation needs to be performed in patients receiving 500 IU
EPO/kg body weight daily for 7 days to avoid iron deple-
tion. In the other trial, three patients in the rhEPO group
suffered venous thrombosis, compared with one patient in
the placebo group. No further adverse side effects, possibly
related to EPO, were encountered in either trial.
In 2005, an in vitro study showed that the serum of
burned mice had elevated EPO levels, and bone marrow
cell cultures treated with this serum reacted with increased
proliferation rates [37].
The fact that no increase in hemoglobin, hematocrit,
reticulocyte or erythrocyte count was found in either
study is an especially interesting aspect regarding the
treatment of burned patients; besides the well-known fact
of decreased EPO efficacy regarding erytropoiesis in inflam-
mation and in trauma situations of the organism, no
explanation for this phenomenon has been given so far.
Known complications of EPO treatment are thrombo-
embolic events. A large multi-center trial investigating
the safety of EPO administration to poly-traumatized
patients demonstrated EPO is safe and beneficial for
these patients and that thromboembolic events were
reduced to ranges seen in poly-traumatized patients
not receiving EPO when combined with an appropriate
anti-thrombotic therapy [38]. As the thromboembolic risk
of thermally injured patients is comparable to that of poly-
traumatized patients, we conclude that EPO administration
in thermally injured patients is safe when combined withan adequate anti-thrombotic prophylaxis as it is done in
our trial.
There are two further well-known adverse events
related to EPO. The first is the increase in blood pressure
in already hypertonic patients [39] with the consequence
that therapy resistant arterial hypertension is an exclusion
criterion of the trial. The second is the unclear situation of
EPO in patients with malignant tumors. In several trials it
was shown that the mortality rate of EPO-treated groups
is higher than for untreated controls [39]. Therefore, a
known malignancy is also an exclusion criterion of the trial.
Age, nutritional status, affected total body surface,
gender, concomitant illnesses, inhalation injury or other
concomitant trauma, as well as wound infections, have a
large influence on the patient’s prognosis, survival rate
and wound healing. Therefore we considered all of these
factors carefully and discussed their relevance for our
primary and secondary endpoints. As we are unable to
foresee which patient group will profit most, we consider
an exclusion of one of this groups as unethical.
Dermal thermal traumas are commonly seen in two
age groups of adults. The first group comprises young
adults aged between 18 and 28 and the second group
comprises elderly persons aged over 65 years. As we are
not able to foresee which of these groups would benefit
most from pro-regenerative treatment, we decided to
include patients aged 18 to 75 in our study [40].
The nutrition of burns patients is also a very exten-
sively discussed topic, but so far no official guidelines
exist and scientific evidence is not satisfactory. Thus we
accepted the regulations of the burns centers and their
in-house nutrition regimes. The authors expect that
this will influence the results and they will consider
this very carefully during the evaluation. This is one
of the reasons why we have an adjustment for the
centers (hospital).
The severity of the injury (affected total body surface
and burn degree) has a significant influence on the prog-
nosis of the patient, especially in combination with age
and gender. Here again we are unable to foresee which
patient group will profit most.
Concomitant illnesses are important factors especially
if they interact with EPO. Thus, as stated above, we
exclude patients with illnesses such as hypertension,
malignant diseases, etc.
Interesting first reports concerning the prevention of
burn progression by systemic administration of EPO in a
rat model have been given as congress reports. These
promising results need further investigation [41].
We hypothesize, therefore, that EPO can protect the
epidermis, dermis and its vital structures – especially the
capillaries and blood vessels – from further damage, for
example, further burn progression. This very often in-
creases the depth of the thermal injury and, therefore,
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a time frame during which its anti-apoptotic action can
prevent the increase of the penumbra.
Overall, we expect EPO treatment in thermally injured
patients to be safe and beneficial when combined with
an adequate anti-thrombotic prophylaxis, as has already
been seen for decades in patients with anemia due to
renal failure.
In conclusion, we expect that because of the tissue and
cell-protective effects (anti-apoptotic, anti-inflammatory,
stem cell recruiting and pro-angiogenic) of EPO, its
biomimetic effects will be useful in the treatment of acute
thermal dermal injuries.
Trial status
This is an investigator-initiated Phase 2a trial funded by
the German Federal Ministry of Education and Research.
Full approval has been given by the ethics committees.
The trial is in the recruitment phase.
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